Investment analysts at Cantor Fitzgerald initiated coverage on Shire plc (SHPG) shares with a Buy rating
Shire recently reported fourth-quarter 2015 non GAAP diluted earnings per ADS of $2.97, representing a 12.8% increase year over year and exceeding the analysts' average estimate of $2.82 earnings per share for the period
Shire said that it expects 2016 to be another strong year of financial performance for the company
Shire's focus is on providing treatments in Rare Diseases, Neuroscience, Gastrointestinal and Internal Medicine and the company is developing treatments for symptomatic conditions treated by specialist physicians in other targeted therapeutic areas, such as Ophthalmics.
Brokerage firm Cantor Fitzgerald also initiated coverage on shares of AstraZeneca PLC (AZN) with a Buy rating
AstraZeneca delivered a strong pipeline and financial performance in 2015, posting core earnings of $4.26 per share, up 7% versus 2014
AstraZenecais a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases.
Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWEWorld Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at www.crweworld.com/finance_disclaimer